StonvexLoading…
StonvexStonvexStonvexCore line items from CBT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-09-30 | Annual 2024 2024-09-30 | Annual 2023 2023-09-30 | Annual 2022 2022-09-30 |
|---|---|---|---|---|
Revenue | $3.71B | $3.99B | $3.93B | $4.32B |
Operating Income | $621.00M | $614.00M | $526.00M | $389.00M |
Net Income | $331.00M | $380.00M | $445.00M | $209.00M |
EPS (Diluted) | $6.02 | $6.72 | $7.73 | $3.62 |
Total Assets | $3.81B | $3.74B | $3.60B | $3.52B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $258.00M | $223.00M | $238.00M | $206.00M |
Free Cash Flow OCF − CapEx | $391.00M | $451.00M | $351.00M | $-111.00M |
Shares Outstanding | 52.84M | 54.30M | 55.24M | 56.25M |